Merck & Co., Inc. is 44.9x more valuable than Spyre Therapeutics, Inc. by market capitalization ($293.16 B vs $6.53 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | SYRE | MRK |
|---|---|---|
| Market cap | $6.53 B | $293.16 B |
| US-listed rank | #1200 | #44 |
| Revenue (latest FY) | $0.00 | $65.01B |
| Net income (latest FY) | -$155.20M | $18.25B |
| Net margin | - | 28.1% |
| P/E (trailing FY) | - | 16.1 |
| SEC filings | 762 | 996 |
Merck & Co., Inc. is 44.9x more valuable than Spyre Therapeutics, Inc. by market capitalization ($293.16 B vs $6.53 B).
In their latest fiscal years, Spyre Therapeutics, Inc. reported $0.00 in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: Spyre Therapeutics, Inc. and Merck & Co., Inc., or browse the full rankings.